Skip to content

New US HIV lipid guidelines favour lifestyle changes over drug therapy as first line

HAART optimism means HIV-positive IV drug users more likely to have unsafe sex and share needles

Nevirapine for PEP: should use be restricted due to liver toxicity risk?

Computer model says vaccines and treatment both needed to turn tide of HIV

Success and failure in HIV treatment: contrasting lessons from South Africa

T-20 for post-exposure prophylaxis?

Six months of DOT achieves undetectable HIV viral load in both genital tract and plasma

Initial HAART regimen lasts only 1.6 years in antiretroviral-naive

Efavirenz, indinavir and abacavir most potent antiretrovirals in pre-2001 study